Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | CYP4Z1 | Q86W10 | 3/20 | 0.39 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.39 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6775482 | 0.89 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2LMNACYP1A2CYP3A4 | |
| SCHEMBL6774237 | 0.83 | NAMPT (0.42) | ALDH1A1LMNACYP4F2CYP4A11CYP4Z1 | |
| SCHEMBL6771650 | 0.82 | CNR2 (0.45) | ALDH1A1CYP4F2CYP4A11CYP4Z1CYP4F11 | |
| SCHEMBL6782416 | 0.80 | PPID (0.47) | ALDH1A1LMNACYP1A2CYP3A4CYP4F2 | |
| SCHEMBL6775475 | 0.80 | CNR2 (0.48) | ALDH1A1TSHRCYP4F2CYP4A11CYP4Z1 | |
| SCHEMBL20502747 | 0.79 | ALDH1A1 (0.68) | ALDH1A1POLBKMT2A | |
| SCHEMBL6781100 | 0.78 | ALDH1A1 (0.45) | ALDH1A1LMNACYP4F2CYP4A11CYP4Z1 | |
| SCHEMBL6774976 | 0.78 | POLB (0.47) | ALDH1A1SMN1; SMN2LMNACYP2C19CYP4F2 | |
| SCHEMBL27541550 | 0.78 | NAMPT (0.57) | ALDH1A1LMNACYP4F2CYP4A11KMT2A | |
| SCHEMBL7619439 | 0.77 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2CYP4F2CYP4A11HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833382-B2 | By muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines; mutant strain employed is preferably derived from the strain S. pristinaespiralis SP92 | AVENTIS PHARMA S.A. (FR) | 2004-12-21 | — | — | US | disclosed |
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | AVENTIS PHARMA, S.A. | 2002-10-03 | — | — | US | disclosed |
| US-6384014-B1 | ANTIBIOTICS AS BACTERICIDES | AVENTIS PHARMA S.A. (FR) | 2002-05-07 | — | — | US | disclosed |
| US-6352839-B1 | PREPARING VIRGINIAMYCINS FROM AN ENGINEERED MICROORGANISMS, HAVING THE ABILITY TO PREVENT BIOSYNTHESIS OF THE PRECURSOR ANTIBIOTIC; THE MICROORGANISM IS CULTURED IN THE PRESENCE OF A SECOND PRECURSOR AND THE STREPTOGRAMIN ANALOG IS RECOVERED | AVENTIS PHARMA S.A. (FR) | 2002-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | EMG1, FBL, SMS | ALDH1A1 3856/4885SMN1; SMN2 2700/4885LMNA 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.